Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis-Reference-Cited by-同舟云学术

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

Published:2019-02-04 Issue:5 Volume:180 Page:1248-1249
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Bakker D.S.¹,Ariens L.F.M.¹,Luijk C.²,Schaft J.¹,Thijs J.L.¹,Schuttelaar M.L.A.³,Wijk F.⁴,Knol E.F.¹⁴,Balak D.M.W.¹,Dijk M.R.⁵,Bruin‐Weller M.S.¹^ORCID

Affiliation:

1. National Expertise Center for Atopic Dermatitis Department of Dermatology and Allergology University Medical Center Utrecht Utrecht the Netherlands

2. Department of Ophthalmology University Medical Center Utrecht Utrechtthe Netherlands

3. Department of Dermatology University Medical Center Groningen University of Groningen Groningen the Netherlands

4. Laboratory of Translational Immunology University Medical Center Utrecht Utrechtthe Netherlands

5. Department of Pathology University Medical Center Utrecht Utrecht the Netherlands

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.17538

Reference8 articles.

1. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

2. Goblet cells of the conjunctiva: A review of recent findings

3. Distribution and density of conjunctival goblet cells

4. IL-13 Stimulates Proliferation and Expression of Mucin and Immunomodulatory Genes in Cultured Conjunctival Goblet Cells

5. Conjunctival Epithelial Cell Hypermitosis and Goblet Cell Hyperplasia in Atopic Keratoconjunctivitis

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis;Frontiers in Pharmacology;2024-08-01

2. Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis;Clinical and Translational Allergy;2024-08

3. Cendakimab in Patients With Moderate to Severe Atopic Dermatitis;JAMA Dermatology;2024-08-01

4. Biological Therapies for Pediatric Atopic Dermatitis - A Review;Current Pediatric Reviews;2024-08

5. An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis;Pediatric Allergy and Immunology;2024-06